Literature DB >> 11162590

Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells.

S Y Sun1, P Yue, J Y Zhou, Y Wang, H R Choi Kim, R Lotan, G S Wu.   

Abstract

The tumor necrosis factor (TNF) related apoptosis-inducing ligand (TRAIL or Apo2L) and its receptors are members of the tumor necrosis factor superfamily. TRAIL triggers apoptosis by binding to its two proapoptotic receptors DR4 and DR5, a process which is negatively regulated by binding of TRAIL to its two decoy receptors TRID and TRUNDD. Here, we show that TRAIL effectively induces apoptosis in H460 human non-small-cell lung carcinoma cells via cleavage of caspases 8, 9, 7, 3, and BID, release of cytochrome c from the mitochondria, and cleavage of poly (ADP-ribose) polymerase (PARP). However, overexpression of Bcl2 blocked TRAIL-induced apoptosis in H460 cells, which correlated with the Bcl2 protein levels. Importantly, the release of cytochrome c and cleavage of caspase 7 triggered by TRAIL were considerably blocked in Bcl2 overexpressing cells as compared to vector control cells. Moreover, inhibition of TRAIL-mediated cytochrome c release and caspase 7 activation by Bcl2 correlated with the inability of PARP to be cleaved and the inability of the Bcl2 transfectants to undergo apoptosis. Thus, these results suggest that Bcl2 can serve an anti-apoptotic function during TRAIL-dependent apoptosis by inhibiting the release of cytochrome c and activation of caspase 7, thereby blocking caspase 7-dependent cleavage of cellular substrates. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11162590     DOI: 10.1006/bbrc.2000.4218

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  31 in total

1.  Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Alexander Kotelkin; Elena A Prikhod'ko; Jeffrey I Cohen; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

2.  Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF.

Authors:  Terri B Hunter; Neil J Manimala; Kimberly A Luddy; Tracy Catlin; Scott J Antonia
Journal:  Anticancer Res       Date:  2011-10       Impact factor: 2.480

3.  The DeISGylase USP18 limits TRAIL-induced apoptosis through the regulation of TRAIL levels: Cellular levels of TRAIL influences responsiveness to TRAIL-induced apoptosis.

Authors:  Ivana Manini; Andrea Sgorbissa; Harish Potu; Andrea Tomasella; Claudio Brancolini
Journal:  Cancer Biol Ther       Date:  2013-09-19       Impact factor: 4.742

Review 4.  Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy.

Authors:  Xiaoyun Dai; Jingwen Zhang; Frank Arfuso; Arunachalam Chinnathambi; M E Zayed; Sulaiman Ali Alharbi; Alan Prem Kumar; Kwang Seok Ahn; Gautam Sethi
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-07

Review 5.  Combined modality therapy with TRAIL or agonistic death receptor antibodies.

Authors:  Hope M Amm; Patsy G Oliver; Choo Hyung Lee; Yufeng Li; Donald J Buchsbaum
Journal:  Cancer Biol Ther       Date:  2011-03-01       Impact factor: 4.742

Review 6.  Developing TRAIL/TRAIL death receptor-based cancer therapies.

Authors:  Xun Yuan; Ambikai Gajan; Qian Chu; Hua Xiong; Kongming Wu; Gen Sheng Wu
Journal:  Cancer Metastasis Rev       Date:  2018-12       Impact factor: 9.264

Review 7.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

8.  Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells.

Authors:  Jing Xu; Jun-Ying Zhou; Wei-Zen Wei; Gen Sheng Wu
Journal:  PLoS One       Date:  2010-04-19       Impact factor: 3.240

9.  Targeting PP2A inhibits the growth of triple-negative breast cancer cells.

Authors:  Mohammed Hafiz Uddin; Julio M Pimentel; Madhumita Chatterjee; Joshu E Allen; Zhengping Zhuang; Gen Sheng Wu
Journal:  Cell Cycle       Date:  2020-02-03       Impact factor: 4.534

10.  Sp1-mediated TRAIL induction in chemosensitization.

Authors:  Jing Xu; Jun-Ying Zhou; Wei-Zen Wei; Sjaak Philipsen; Gen Sheng Wu
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.